|
|
 |
 | ||
|
|
| ||
|
Research |
|
|
|
The Bone Health Program has been actively involved in exploring the causes and symptoms of pediatric low bone density and researching new and improved treatments. Recent research interests have included:
|
|
|
- Use of Adrenal and Gonadal Hormone Replacement to Prevent Osteoporosis in Anorexia
Nervosa:
A randomized, double-blind placebo-controlled trial examining the effect of oral DHEA and
estrogen/progestin replacement on bone turnover, density and strength in patients with
anorexia nervosa.
- Effect of Hormonal Add-Back Therapy in Adolescents Treated with (GnRH) Agonist Therapy for Endometriosis:
A randomized, double-blinded trial to measure the bones of healthy adolescents with patients with diseases, like anorexia nervosa and endometriosis can be compared.
- Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents with IBD:
Vitamin D is important for growing and maintaining healthy bones throughout life, and this is particularly important since children with IBD frequently have low bone density.
- Bioavailability of Vitamin D in Adolescents and Young Women with Anorexia Nervosa:
This protocol is to compare how vitamin D is absorbed and used by the body in young women with anorexia nervosa and in healthy adolescents.
- Use of Farnesyltransferase inhibitor (FTI) Lonafarnib for Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies:
This protocol measures an experimental drug's effect using many tests in hopes that this drug will have therapeutic effect on progeria.
|
|
Research by Catherine Gordon, MD, MSc, Director of the Bone Health Program
Research by Ingrid Holm, MD, MPH, Associate Director of the Bone Health Program
|
|
|
|
|
|
